Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Trials ; 18(1): 504, 2017 Oct 27.
Article in English | MEDLINE | ID: mdl-29078800

ABSTRACT

BACKGROUND: Meta-analyses of randomized controlled trials (RCTs) have shown that exercise has beneficial effects on quality of life (QoL) in patients with breast cancer. However, these effects were often small. Blinding in an exercise trial is not possible, which has the possible disadvantage of difficult accrual, drop-out after randomization to control and contamination between study groups (controls adopting the behaviour of the intervention group). The cohort multiple randomized controlled trial (cmRCT) is an alternative for conventional RCTs and has the potential to overcome these disadvantages. METHODS: This cmRCT will be performed within the Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA). Patients with breast cancer who visit the radiotherapy department of the University Medical Center Utrecht are asked to participate in UMBRELLA. Patients give consent for collection of medical information, providing patient-reported outcomes through regular questionnaires and randomization into future intervention studies. Patients who fulfill the UMBRELLA Fit study eligibility criteria (12 to 18 months post inclusion in UMBRELLA, low physical activity level) will be randomly allocated to the intervention or control group (1:1 ratio). Patients randomized to the intervention group will be offered a 12-week exercise programme. The control group will not be informed. Regular cohort measurements will be used for outcome assessment. Feasiblity (including participation, contamination, generalizability and retention) of the cmRCT design and effects of the intervention on QoL will be evaluated. DISCUSSION: We will examine the feasibility of the cmRCT design in exercise-oncology research and compare this with conventional RCTs. Furthermore, the effectiveness of an exercise intervention on the QoL of patients with breast cancer in the short term (6 months) and long term (24 months) will be studied. TRIAL REGISTRATION: Netherlands Trial Register, NTR5482/NL.52062.041.15 . Retrospectively registered on 7 December 2015.


Subject(s)
Breast Neoplasms/therapy , Exercise Therapy , Quality of Life , Adolescent , Adult , Aged , Breast Neoplasms/diagnosis , Breast Neoplasms/psychology , Clinical Protocols , Feasibility Studies , Female , Humans , Mastectomy , Middle Aged , Netherlands , Radiotherapy, Adjuvant , Research Design , Time Factors , Treatment Outcome , Young Adult
2.
BMC Pulm Med ; 11: 43, 2011 Aug 19.
Article in English | MEDLINE | ID: mdl-21854576

ABSTRACT

BACKGROUND: Although timely treatment of COPD exacerbations seems clinically important, nearly half of these exacerbations remain unreported and subsequently untreated. Recent studies have investigated incidence and impact of failure to seek medical treatment during exacerbations. Yet, little is known about type and timing of other self-management actions in periods of symptom deterioration. The current prospective study aims at determining the relative incidence, timing and determinants of three types of patient responses. METHODS: In a multicentre observational study, 121 patients (age 67 ± 11 years, FEV1pred. 48 ± 19) were followed for 6 weeks by daily diary symptom recording. Three types of action were assessed daily: planning periods of rest, breathing techniques and/or sputum clearing (type-A), increased bronchodilator use (type-B) and contacting a healthcare provider (type-C). RESULTS: Type-A action was taken in 70.7%, type-B in 62.7% and type C in 17.3% of exacerbations (n = 75). Smokers were less likely to take type-A and B actions. Type-C actions were associated with more severe airflow limitation and increased number of hospital admissions in the last year. CONCLUSIONS: Our study shows that most patients are willing to take timely self-management actions during exacerbations. Future research is needed to determine whether the low incidence of contacting a healthcare provider is due to a lack of self-management or healthcare accessibility.


Subject(s)
Breathing Exercises , Bronchodilator Agents/therapeutic use , Physician-Patient Relations , Pulmonary Disease, Chronic Obstructive/therapy , Rest , Sputum , Aged , Female , Health Services Accessibility , Humans , Incidence , Male , Middle Aged , Patient Participation , Prospective Studies , Self Care , Time Factors , Treatment Outcome
3.
Int J Radiat Oncol Biol Phys ; 81(3): 737-44, 2011 Nov 01.
Article in English | MEDLINE | ID: mdl-20888131

ABSTRACT

PURPOSE: Acute urinary retention (AUR) after iodine-125 (I-125) prostate brachytherapy negatively influences long-term quality of life and therefore should be prevented. We aimed to develop a nomogram to preoperatively predict the risk of AUR. METHODS: Using the preoperative data of 714 consecutive patients who underwent I-125 prostate brachytherapy between 2005 and 2008 at our department, we modeled the probability of AUR. Multivariate logistic regression analysis was used to assess the predictive ability of a set of pretreatment predictors and the additional value of a new risk factor (the extent of prostate protrusion into the bladder). The performance of the final model was assessed with calibration and discrimination measures. RESULTS: Of the 714 patients, 57 patients (8.0%) developed AUR after implantation. Multivariate analysis showed that the combination of prostate volume, IPSS score, neoadjuvant hormonal treatment and the extent of prostate protrusion contribute to the prediction of AUR. The discriminative value (receiver operator characteristic area, ROC) of the basic model (including prostate volume, International Prostate Symptom Score, and neoadjuvant hormonal treatment) to predict the development of AUR was 0.70. The addition of prostate protrusion significantly increased the discriminative power of the model (ROC 0.82). Calibration of this final model was good. The nomogram showed that among patients with a low sum score (<18 points), the risk of AUR was only 0%-5%. However, in patients with a high sum score (>35 points), the risk of AUR was more than 20%. CONCLUSION: This nomogram is a useful tool for physicians to predict the risk of AUR after I-125 prostate brachytherapy. The nomogram can aid in individualized treatment decision-making and patient counseling.


Subject(s)
Brachytherapy/adverse effects , Iodine Radioisotopes/adverse effects , Nomograms , Prostate/pathology , Prostatic Neoplasms/radiotherapy , Urinary Retention/etiology , Aged , Androgen Antagonists/administration & dosage , Brachytherapy/methods , Chemotherapy, Adjuvant , Decision Making , Discriminant Analysis , Humans , Iodine Radioisotopes/therapeutic use , Male , Observer Variation , Organ Size , Prostatic Neoplasms/pathology , Quality of Life , ROC Curve , Regression Analysis , Risk Assessment , Urinary Bladder/pathology , Urinary Retention/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL